Keywords: مهار کننده های مجاهدین خلق; Tumor micro-environment; Immunotherapy; Immune checkpoint inhibitors; BRAF inhibitors; MEK inhibitors; Resistance mechanisms; Outcomes; Combination immunotherapy; Targeted therapy;
مقالات ISI مهار کننده های مجاهدین خلق (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده های مجاهدین خلق; cuSCC; cutaneous squamous cell carcinoma; ERK; extracellular signal-regulated kinase; MEK; mitogen-activated protein kinase/ERK kinase; MEKi; MEK inhibitors;
Keywords: مهار کننده های مجاهدین خلق; Allosteric inhibitors; Serine/threonine kinase; Tyrosine kinase; MEK inhibitors; Type III inhibitors; Type IV inhibitors; AGC; containing protein kinase A, protein kinase G, protein kinase C families; ATP; adenosine 5â²-triphosphate; CAMK; calcium/calmod
Discovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold
Keywords: مهار کننده های مجاهدین خلق; Kinase; MEK inhibitors; Scaffold hopping; Benzofuran;
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma
Keywords: مهار کننده های مجاهدین خلق; Metastatic melanoma; PD-L1 expression; BRAF mutation; BRAF inhibitors; MEK inhibitors; Biomarker;
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Keywords: مهار کننده های مجاهدین خلق; Binimetinib (PubChem CID: 10288191); Cobimetinib (PubChem CID: 16222096); Dabrafenib (PubChem CID: 44462760); Encorafenib (PubChem CID: 50922675); Trametinib (PubChem CID: 11707110); Vemurafenib (PubChem CID: 42611257); ATC; adoptively transferred T cells
An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients
Keywords: مهار کننده های مجاهدین خلق; BRAFi; BRAF inhibitors; MEKi; MEK inhibitors; Cmin; Trough concentration; CV; Coefficient of variation; EMA; European Medical Agency; ESI; Electrospray ionization; LC-UV; Liquid chromatography combined to UV detection; LLOQ; Low limit of quantification; M
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
Keywords: مهار کننده های مجاهدین خلق; Pancreatic ductal adenocarcinoma; KRAS mutation; Quantitative PCR; Solid pancreatic masses; Prognosis; MEK inhibitors;
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
Keywords: مهار کننده های مجاهدین خلق; BRAF mutations; BRAF inhibitors; MEK inhibitors; Melanoma; Resistance; Targeted therapy
MEK1/2 inhibitors in the treatment of gynecologic malignancies
Keywords: مهار کننده های مجاهدین خلق; MEK inhibitors; Cancer; Ovarian; Serous; Low grade; MAPK cascade
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
Keywords: مهار کننده های مجاهدین خلق; ERK inhibitors; BRAF inhibitors; MEK inhibitors; Melanoma; Acquired resistance;
Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells
Keywords: مهار کننده های مجاهدین خلق; MEK inhibitors; FOXO1; Platinum compounds; Ovarian carcinoma; Drug resistance
Ovarian low-grade serous carcinoma: A comprehensive update
Keywords: مهار کننده های مجاهدین خلق; Serous ovarian cancer; Low-grade; RAS; MEK inhibitors; Cytoreductive surgery
Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines
Keywords: مهار کننده های مجاهدین خلق; Alkylphosphocholines; Erufosine; Perifosine; Multiple myeloma; Interleukin-6; Osteopontin; Raf/MEK/ERK; MEK inhibitors; Drug resistance
The flavonoid fisetin promotes nerve cell survival from trophic factor withdrawal by enhancement of proteasome activity
Keywords: مهار کننده های مجاهدین خلق; Neuroprotection; ERK; Lactacystin; MEK inhibitors; Glutathione
Is the focus moving toward a combination of targeted drugs?
Keywords: مهار کننده های مجاهدین خلق; targeted agents; histone deacetylase inhibitors; HDAC; NF-κB inhibitors; CDK inhibitors; proteasome inhibitors; MEK inhibitors; BCL-2 inhibitors
Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2′-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB
Keywords: مهار کننده های مجاهدین خلق; MAPK/ERK pathway; 2-Chloro-2′-deoxyadenosine; EHEB; MEK inhibitors; Caspase-3; Chronic lymphocytic leukemia
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies
Keywords: مهار کننده های مجاهدین خلق; Targeted therapy; Drug resistance; Combination therapy; Molecular markers; EGFR; IGFR1; MAPK; MEK inhibitors; AML